A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of Once-daily Oral Avatrombopag in Japanese Subjects With Chronic Liver Disease and Thrombocytopenia
Phase of Trial: Phase II
Latest Information Update: 04 Mar 2019
Price : $35 *
At a glance
- Drugs Avatrombopag (Primary)
- Indications Liver disorders; Thrombocytopenia
- Focus Therapeutic Use
- Sponsors Eisai Co Ltd
- 15 Jun 2018 Results of pooled data from 14 trials, were published in the Journal of Clinical Pharmacology.
- 19 Jun 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 28 Apr 2015 Status changed from recruiting to active, no longer recruiting as per ClinicalTrials.gov record.